Neuroprotection with rasagiline in patients with macula-off retinal detachment: A randomized controlled pilot study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 03 2020
18 03 2020
Historique:
received:
11
09
2019
accepted:
02
03
2020
entrez:
20
3
2020
pubmed:
20
3
2020
medline:
24
11
2020
Statut:
epublish
Résumé
We aimed to evaluate the neuroprotective efficacy of rasagiline in pseudophakic patients who had surgery for macula-off rhegmatogenous retinal detachment (RRD). This was a 6-month, prospective, randomized, double-blind, placebo-controlled pilot study. Patients presenting with acute macula-off RRD were recruited and randomized 1:1 to receive rasagiline 1 mg/day or placebo for 7 days. Best-corrected visual acuity (BCVA) and optical coherence tomography were acquired 1 day before as well as 2 days, 3 weeks, 3 months and 6 months after surgery. We screened 26 patients with RRD whereof 23 were eventually included and randomized. The primary outcome was final BCVA. Secondary outcomes included central retinal thickness (CRT) and adverse events (AE). We evaluated photoreceptor cells (prc) recovery through morphological measurements. The baseline characteristics were comparable between groups. BCVA significantly improved in both groups (letters gained: rasagiline 61.5 ± 18.1 vs placebo 55.3 ± 29.2, p = 0.56), but no significant inter-group difference was found at any visit. CRT was stable 3 weeks after surgery onwards, with no inter-group difference. No treatment-emergent AE occurred. Significant prc restoration was observed from 3 weeks to 6 months after surgery, without inter-group difference at either visit. Ellipsoid zone integrity (β = 0.517, p = 0.008) and foveal bulge (β = 0.387, p = 0.038) were significant predictors of good final BCVA. In conclusion, perioperative oral treatment with rasagiline 1 mg/day for 7 days did not show significant benefits on visual or anatomical outcomes in macula-off RRD patients.
Identifiants
pubmed: 32188915
doi: 10.1038/s41598-020-61835-0
pii: 10.1038/s41598-020-61835-0
pmc: PMC7080767
doi:
Substances chimiques
Indans
0
Neuroprotective Agents
0
rasagiline
003N66TS6T
Types de publication
Clinical Trial
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
4948Références
D’Amico, D. J. Clinical practice. Primary retinal detachment. The New England journal of medicine 359, 2346–2354, https://doi.org/10.1056/NEJMcp0804591 (2008).
doi: 10.1056/NEJMcp0804591
pubmed: 19038880
Van de Put, M. A. J., Hooymans, J. M. M. & Los, L. I. The incidence of rhegmatogenous retinal detachment in The Netherlands. Ophthalmology 120, 616–622, https://doi.org/10.1016/j.ophtha.2012.09.001 (2013).
doi: 10.1016/j.ophtha.2012.09.001
pubmed: 23218185
Wubben, T. J., Besirli, C. G. & Zacks, D. N. Pharmacotherapies for Retinal Detachment. Ophthalmology 123, 1553–1562, https://doi.org/10.1016/j.ophtha.2016.02.040 (2016).
doi: 10.1016/j.ophtha.2016.02.040
pubmed: 27040150
Murakami, Y. et al. Photoreceptor cell death and rescue in retinal detachment and degenerations. Progress in retinal and eye research 37, 114–140, https://doi.org/10.1016/j.preteyeres.2013.08.001 (2013).
doi: 10.1016/j.preteyeres.2013.08.001
pubmed: 23994436
Youdim, M. B. H. Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases. Journal of neural transmission (Vienna, Austria: 1996) 125, 1719–1733, https://doi.org/10.1007/s00702-018-1942-9 (2018).
doi: 10.1007/s00702-018-1942-9
Weinreb, O., Amit, T., Bar-Am, O. & Youdim, M. B. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Progress in neurobiology 92, 330–344, https://doi.org/10.1016/j.pneurobio.2010.06.008 (2010).
doi: 10.1016/j.pneurobio.2010.06.008
pubmed: 20600573
Eigeldinger-Berthou, S. et al. Rasagiline interferes with neurodegeneration in the Prph2/rds mouse. Retina (Philadelphia, Pa.) 32, 617–628, https://doi.org/10.1097/IAE.0b013e31821e2070 (2012).
doi: 10.1097/IAE.0b013e31821e2070
Garcia-Delgado, A. B., Valdes-Sanchez, L., Calado, S. M., Diaz-Corrales, F. J. & Bhattacharya, S. S. Rasagiline delays retinal degeneration in a mouse model of retinitis pigmentosa via modulation of Bax/Bcl-2 expression. CNS neuroscience & therapeutics 24, 448–455, https://doi.org/10.1111/cns.12805 (2018).
doi: 10.1111/cns.12805
Levkovitch-Verbin, H., Vander, S. & Melamed, S. Rasagiline-induced delay of retinal ganglion cell death in experimental glaucoma in rats. Journal of glaucoma 20, 273–277, https://doi.org/10.1097/IJG.0b013e3181e3d101 (2011).
doi: 10.1097/IJG.0b013e3181e3d101
pubmed: 20577110
Lei, D., Shao, Z., Zhou, X. & Yuan, H. Synergistic neuroprotective effect of rasagiline and idebenone against retinal ischemia-reperfusion injury via the Lin28-let-7-Dicer pathway. Oncotarget 9, 12137–12153, https://doi.org/10.18632/oncotarget.24343 (2018).
doi: 10.18632/oncotarget.24343
pubmed: 29552298
pmcid: 5844734
Poewe, W. et al. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. The Lancet. Neurology 14, 145–152, https://doi.org/10.1016/s1474-4422(14)70288-1 (2015).
doi: 10.1016/s1474-4422(14)70288-1
pubmed: 25498732
Park, D. H., Choi, K. S., Sun, H. J. & Lee, S. J. Factors associated with visual outcome after macula-off rhegmatogenous retinal detachment surgery. Retina (Philadelphia, Pa.) 38, 137–147, https://doi.org/10.1097/iae.0000000000001512 (2018).
doi: 10.1097/iae.0000000000001512
Hasegawa, T., Ueda, T., Okamoto, M. & Ogata, N. Relationship between presence of foveal bulge in optical coherence tomographic images and visual acuity after rhegmatogenous retinal detachment repair. Retina (Philadelphia, Pa.) 34, 1848–1853, https://doi.org/10.1097/iae.0000000000000160 (2014).
doi: 10.1097/iae.0000000000000160
Adelman, R. A., Parnes, A. J. & Ducournau, D. Strategy for the management of uncomplicated retinal detachments: the European vitreo-retinal society retinal detachment study report 1. Ophthalmology 120, 1804–1808, https://doi.org/10.1016/j.ophtha.2013.01.070 (2013).
doi: 10.1016/j.ophtha.2013.01.070
pubmed: 23601799
Surgucheva, I., Ninkina, N., Buchman, V. L., Grasing, K. & Surguchov, A. Protein aggregation in retinal cells and approaches to cell protection. Cellular and molecular neurobiology 25, 1051–1066, https://doi.org/10.1007/s10571-005-8474-1 (2005).
doi: 10.1007/s10571-005-8474-1
pubmed: 16392036
Gotz, M. E. et al. Chronic TVP-1012 (rasagiline) dose–activity response of monoamine oxidases A and B in the brain of the common marmoset. Journal of neural transmission. Supplementum 52, 271–278 (1998).
doi: 10.1007/978-3-7091-6499-0_27
Stefanova, N., Poewe, W. & Wenning, G. K. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Experimental neurology 210, 421–427, https://doi.org/10.1016/j.expneurol.2007.11.022 (2008).
doi: 10.1016/j.expneurol.2007.11.022
pubmed: 18222424
Hauser, R. A. et al. Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned. JAMA neurology 72, 1491–1500, https://doi.org/10.1001/jamaneurol.2015.2268 (2015).
doi: 10.1001/jamaneurol.2015.2268
pubmed: 26523919
Arroyo, J. G., Yang, L., Bula, D. & Chen, D. F. Photoreceptor apoptosis in human retinal detachment. American journal of ophthalmology 139, 605–610, https://doi.org/10.1016/j.ajo.2004.11.046 (2005).
doi: 10.1016/j.ajo.2004.11.046
pubmed: 15808154
Youdim, M. B., Gross, A. & Finberg, J. P. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. British journal of pharmacology 132, 500–506, https://doi.org/10.1038/sj.bjp.0703826 (2001).
doi: 10.1038/sj.bjp.0703826
pubmed: 11159700
pmcid: 1572573
Ahn, S. J., Park, S. H. & Lee, B. R. Visualization of the macula in gas-filled eyes: spectral domain optical coherence tomography versus swept-source optical coherence tomography. Retina (Philadelphia, Pa.) 38, 480–489, https://doi.org/10.1097/iae.0000000000001560 (2018).
doi: 10.1097/iae.0000000000001560
Solberg, Y. et al. Retinal flecks in stargardt disease reveal characteristic fluorescence lifetime transition over time. Retina (Philadelphia, Pa.) 39, 879–888, https://doi.org/10.1097/iae.0000000000002519 (2019).
doi: 10.1097/iae.0000000000002519
Dysli, C. et al. Fluorescence lifetime imaging ophthalmoscopy. Progress in retinal and eye research 60, 120–143, https://doi.org/10.1016/j.preteyeres.2017.06.005 (2017).
doi: 10.1016/j.preteyeres.2017.06.005
pubmed: 28673870
Delolme, M. P. et al. Anatomical and functional macular changes after rhegmatogenous retinal detachment with macula off. American journal of ophthalmology 153, 128–136, https://doi.org/10.1016/j.ajo.2011.06.010 (2012).
doi: 10.1016/j.ajo.2011.06.010
pubmed: 21937016
Chinskey, N. D., Zheng, Q. D. & Zacks, D. N. Control of photoreceptor autophagy after retinal detachment: the switch from survival to death. Investigative ophthalmology & visual science 55, 688–695, https://doi.org/10.1167/iovs.13-12951 (2014).
doi: 10.1167/iovs.13-12951
Campochiaro, P. A. et al. Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion: The RELATE Trial. Ophthalmology 122, 1426–1437, https://doi.org/10.1016/j.ophtha.2015.04.006 (2015).
doi: 10.1016/j.ophtha.2015.04.006
pubmed: 25972260
Kiang, L. et al. Vitreous Cytokine Expression and a Murine Model Suggest a Key Role of Microglia in the Inflammatory Response to Retinal Detachment. Investigative ophthalmology & visual science 59, 3767–3778, https://doi.org/10.1167/iovs.18-24489 (2018).
doi: 10.1167/iovs.18-24489
Martinez-Castillo, V. J., Garcia-Arumi, J. & Boixadera, A. Pars Plana Vitrectomy Alone for the Management of Pseudophakic Rhegmatogenous Retinal Detachment with Only Inferior Breaks. Ophthalmology 123, 1563–1569, https://doi.org/10.1016/j.ophtha.2016.03.032 (2016).
doi: 10.1016/j.ophtha.2016.03.032
pubmed: 27126928
Ross, W., Lavina, A., Russell, M. & Maberley, D. The correlation between height of macular detachment and visual outcome in macula-off retinal detachments of < or = 7 days’ duration. Ophthalmology 112, 1213–1217, https://doi.org/10.1016/j.ophtha.2005.01.040 (2005).
doi: 10.1016/j.ophtha.2005.01.040
pubmed: 15921745
van de Put, M. A. J. et al. Postoperative recovery of visual function after macula-off rhegmatogenous retinal detachment. PloS one 9, e99787–e99787, https://doi.org/10.1371/journal.pone.0099787 (2014).
doi: 10.1371/journal.pone.0099787
pubmed: 24927502
pmcid: 4057275
Ahmadieh, H. et al. Anatomic and visual outcomes of scleral buckling versus primary vitrectomy in pseudophakic and aphakic retinal detachment: six-month follow-up results of a single operation–report no. 1. Ophthalmology 112, 1421–1429, https://doi.org/10.1016/j.ophtha.2005.02.018 (2005).
doi: 10.1016/j.ophtha.2005.02.018
pubmed: 15961159
Pastor, J. C. et al. Proliferative vitreoretinopathy: A new concept of disease pathogenesis and practical consequences. Progress in retinal and eye research 51, 125–155, https://doi.org/10.1016/j.preteyeres.2015.07.005 (2016).
doi: 10.1016/j.preteyeres.2015.07.005
pubmed: 26209346
Enders, P., Schick, T., Schaub, F., Kemper, C. & Fauser, S. Risk of multiple recurring retinal detachment after primary rhegmatogenous retinal detachment repair. Retina (Philadelphia, Pa.) 37, 930–935, https://doi.org/10.1097/iae.0000000000001302 (2017).
doi: 10.1097/iae.0000000000001302
Menke, M. N. et al. Retinal layer measurements after successful macula-off retinal detachment repair using optical coherence tomography. Investigative ophthalmology & visual science 55, 6575–6579, https://doi.org/10.1167/iovs.14-14412 (2014).
doi: 10.1167/iovs.14-14412
Nakanishi, H. et al. Spectral-domain optical coherence tomography imaging of the detached macula in rhegmatogenous retinal detachment. Retina (Philadelphia, Pa.) 29, 232–242, https://doi.org/10.1097/IAE.0b013e31818bcd30 (2009).
doi: 10.1097/IAE.0b013e31818bcd30
Kobayashi, M. et al. Association Between Photoreceptor Regeneration and Visual Acuity Following Surgery for Rhegmatogenous Retinal Detachment. Investigative ophthalmology & visual science 57, 889–898, https://doi.org/10.1167/iovs.15-18403 (2016).
doi: 10.1167/iovs.15-18403
dell’Omo, R. et al. Restoration of foveal thickness and architecture after macula-off retinal detachment repair. Investigative ophthalmology & visual science 56, 1040–1050, https://doi.org/10.1167/iovs.14-15633 (2015).
doi: 10.1167/iovs.14-15633
Whitehead, A. L., Julious, S. A., Cooper, C. L. & Campbell, M. J. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Statistical methods in medical research 25, 1057–1073, https://doi.org/10.1177/0962280215588241 (2016).
doi: 10.1177/0962280215588241
pubmed: 26092476